The dossier submitted to EFSA was based on several studies including newly developed science, and shows that oligofructose has a significant part to play in the area of glycaemic control.
The application targeted an EU Art 13.5 claim on the contribution of oligofructose to a reduction of post-prandial blood glucose response. EFSA’s positive evaluation allows the approval by the Commission, the member states and the European Parliament within the health claim procedure.
This proprietary new research from Beneo, Cosucra and Sensus has shown the positive impact on blood glucose response when a proportion of the sugars in a product is replaced with the prebiotic fibre oligofructose that is derived from chicory.
The new oligofructose data demonstrates a significantly lower blood glucose response with only 20% replacement. The conditions of use proposed in the evaluation refer to the ‘reduced sugars’ claim as published in the annex of Regulation (EC) No 1924/2006 (ie a 30% replacement).
A second dossier focusing on chicory inulin, and including additional newly developed scientific research, was ready for submission at the moment when EFSA’s opinion on chicory oligofructose was published. As EFSA broadened the scope to non-digestible carbohydrates when evaluating the oligofructose dossier chicory inulin is included and benefits de facto from this evaluation.
Source: Beneo
© FoodBev Media Ltd 2024